Testing dasatinib to shrink HIV reservoir
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HIV and be on the same effective HIV medications for at least 4 years without interruption.
- Your viral load must be undetectable for more than 3 years and be undetectable now.
- Your CD4 count must be above 450 within the last year.
- You need to have healthy blood cell counts, liver and kidney function, and a normal heart rhythm (QTc interval).
- You cannot be pregnant or breastfeeding, and must use effective birth control if sexually active.
- You cannot have certain other medical conditions or take certain medications that might interfere with the study.
- fitModel
- tags_snake_case_identifier
- text_snake_case_identifier
- options_snake_case_identifier
- include_if_snake_case_identifier
- fit_snake_case_identifier
- questions_snake_case_identifier
- key_snake_case_identifier
- text_snake_case_identifier
- options_snake_case_identifier
- include_if_snake_case_identifier
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of medicine that aims to wake up HIV hiding in your body's cells by targeting a viral protein called Tat. The goal is to help find a way to clear the virus completely.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.